PharmaTimes on 17. November 2015
The National Institute for Health and Care Excellence has published final draft guidance rejecting the use of Kadcyla (trastuzumab-emtansine) for patients as the first and only targeted chemotherapy for secondary HER2-positive breast cancer, because of its high price tag – around £90,000 per course (list price).
Full article at PharmaTimes: http://www.pharmatimes.com/Article/15-11-17/Roche_s_Kadcyla_too_expensive_for_NHS_says_NICE.aspx